Accute Lymphoblastic Leukemia (Ph-Like)

BCR-ABL1 fusion, also known as the Philadelphia chromosome, is found in 25% of adult acute lymphoblastic leukemia (ALL) patients.¹ Due to its unique clinical features, the alteration is recognized by the World Health Organization as its own leukemia subset (Ph+ ALL). Ph+ ALL survival rates have increased substantially in the past 20 years. Historically, 1-year survival was about 10%; today 30-40% of Ph+ adult patients achieve long-term remission.1 Despite this progress, PH+ adult ALL remains a high-risk subtype.